- ISIN
- US52490G1022
- CUSIP
- 52490G102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 5, 2020
Highlights
- Market Cap
- $2.72B
- Enterprise Value
- $2.74B
- EPS (TTM)
- -$1.55
- Total Revenue (TTM)
- $1.14B
- Gross Profit (TTM)
- $611.63M
- EBITDA (TTM)
- -$186.04M
- Year Range
- $16.24 - $45.30
- Target Price
- $58.00
- ROA (TTM)
- -15.69%
- ROE (TTM)
- -25.89%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
LEGN Performance Chart
Legend Biotech Corporation (LEGN) is up 35.0% since the beginning of the year. At $29 per share, LEGN is trading 35.2% below its 52-week high of $45. Investors who bought $1,000 worth of LEGN shares 5 years ago would now be looking at an investment worth $718.
Loading charts...
Returns By Period
Legend Biotech Corporation (LEGN) has returned 34.96% so far this year and -13.71% over the past 12 months.
Legend Biotech Corporation
- 1D
- 5.05%
- 1M
- -0.10%
- YTD
- 34.96%
- 6M
- 29.31%
- 1Y
- -13.71%
- 3Y*
- -26.63%
- 5Y*
- -6.42%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
LEGN Monthly Returns History
Based on dividend-adjusted daily data since Jun 5, 2020, LEGN's average daily return is +0.05%, while the average monthly return is +0.63%. At this rate, an investment would double in approximately 9.2 years.
Historically, 44% of months were positive and 56% were negative. The best month was Apr 2023 with a return of +42.5%, while the worst month was Dec 2024 at -22.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.
On a daily basis, LEGN closed higher 47% of trading days. The best single day was Jun 2, 2026 with a return of +42.2%, while the worst single day was Jun 18, 2026 at -16.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.50% | 8.57% | -4.79% | 30.02% | 15.48% | 8.03% | 34.96% | ||||||
| 2025 | 17.09% | -8.11% | -3.08% | 3.01% | -17.17% | 22.59% | 10.09% | -11.11% | -6.10% | -0.64% | -14.48% | -21.54% | -33.19% |
| 2024 | -8.49% | 18.34% | -13.92% | -22.02% | -8.53% | 10.70% | 27.32% | 2.06% | -15.33% | -7.61% | -6.55% | -22.65% | -45.92% |
| 2023 | 1.16% | -8.55% | 4.42% | 42.49% | -6.61% | 7.57% | 9.40% | -8.16% | -3.16% | -1.64% | -7.95% | -1.07% | 20.53% |
| 2022 | -8.52% | -7.15% | -8.21% | 10.48% | 5.33% | 30.05% | -14.11% | -1.59% | -12.24% | 22.11% | 3.39% | -3.09% | 7.10% |
| 2021 | -10.26% | 7.56% | 6.77% | 3.72% | 30.80% | 4.27% | 4.82% | -11.02% | 32.04% | 3.84% | -1.89% | -9.51% | 65.52% |
Benchmark Metrics
Legend Biotech Corporation has an annualized alpha of -0.39%, beta of 0.74, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since June 05, 2020.
- This stock participated in 102.36% of S&P 500 Index downside but only 35.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.39%
- Beta
- 0.74
- R²
- 0.05
- Upside Capture
- 35.49%
- Downside Capture
- 102.36%
Return for Risk
Risk / Return Rank
LEGN ranks 36 for risk / return — below 36% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Legend Biotech Corporation (LEGN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LEGN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.23 | ||
| Sortino ratioReturn per unit of downside risk | -2.55 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.37 | -0.34 |
| Calmar ratioReturn relative to maximum drawdown | -0.22 | 2.78 | -3.00 |
| Martin ratioReturn relative to average drawdown | -0.34 | 12.44 | -12.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Legend Biotech Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Legend Biotech Corporation was 78.24%, occurring on Feb 4, 2026. The portfolio has not yet recovered.
The current Legend Biotech Corporation drawdown is 61.65%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -78.24%Feb 2026 | 2y 6mo | — | 2y 10moJul 2023 - now |
Bear market2022 | -45.56%Mar 2022 | 5mo 3d | 3mo 23d | 8mo 26dOct 2021 - Jul 2022 |
2021 bear market2021 | -44.67%Mar 2021 | 8mo 6d | 4mo 17d | 1y 18dJul 2020 - Jul 2021 |
Bear market2022 | -32.84%Sep 2022 | 2mo 23d | 3mo 18d | 6mo 11dJul 2022 - Jan 2023 |
2021 bear market2021 | -28.01%Aug 2021 | 27d | 1mo 12d | 2mo 9dJul 2021 - Sep 2021 |
Drawdown Indicators
| LEGN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.24% | -56.78% | -21.46% |
Max Drawdown (1Y)Largest decline over 1 year | -62.43% | -9.10% | -53.33% |
Max Drawdown (3Y)Largest decline over 3 years | -78.24% | -18.90% | -59.34% |
Max Drawdown (5Y)Largest decline over 5 years | -78.24% | -25.43% | -52.81% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -61.65% | -1.80% | -59.85% |
Average DrawdownAverage peak-to-trough decline | -31.52% | -10.71% | -20.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 39.81% | 2.03% | +37.78% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Legend Biotech Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Legend Biotech Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for LEGN relative to other companies in the Biotechnology industry. Currently, LEGN has a P/S ratio of 4.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for LEGN in comparison with other companies in the Biotechnology industry. Currently, LEGN has a P/B value of 2.8. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with LEGN
Add Legend Biotech Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with LEGN